Overview

Catherine Longeval specialises in litigation before the Belgian courts and advises clients on a wide range of issues, including life sciences law. Her expertise in this area covers laws governing medicines, biotech products, medical devices, cosmetics and food supplements, among other aspects.

She also specialises in unfair market practices, distribution law, product liability, employment law and general commercial law.

Catherine began her professional career in October 1989. Prior to joining Van Bael & Bellis in 1994, she worked as an associate with a leading Brussels law firm. 

She regularly lectures and writes on life sciences regulatory matters and procedural law matters. She often speaks at conferences.

Languages

Dutch, English, French

Recommendations

  • Chambers Global and Chambers Europe for Dispute Resolution
  • Chambers Europe – ‘Leaders In Their Field’ (Dispute Resolution) 
  • Expert Guides – Guide to the World’s Leading Litigation Lawyers
  • PLC for EU Life Sciences – Regulatory
  • PLC for EU Life Sciences – Competition/Anti-trust
  • PLC for Dispute Resolution 
  • PLC for Belgium Life Sciences – Regulatory
  • Legal 500 for Employment law
  • Legal 500 for Dispute Resolution
  • European Legal Experts for Litigation
  • Who’s Who Legal for Life Sciences
  • LMG Life Sciences (Europe) – Life Sciences Star
  • Best Lawyers – Litigation  

Education

  • University of Brussels (ULB), Master of Laws, 1989 
  • University of Leuven, Master of Laws, 1987

Publications

Contributor to Van Bael & Bellis' Business Law Guide to Belgium (Kluwer Law International/Bruylant, 2003).

Co-author of PLC's Life Sciences Handbook, Chambers' Pharmaceutical Advertising Guide, and dispute resolution section of Chambers' Litigation guide. 

Professional Memberships

Member of CEPINA (Belgian Centre for Mediation and Arbitration)
Member of the Brussels Pharma Law Group
Member of the European Employment Lawyers Association
Member of the International Bar Association

Bar Admission

Brussels

Notable assignments

  • Representing a global pharmaceutical company in the context of “extreme urgency” suspension proceedings before the Council of State, aimed at the suspension and annulment of a tender decision of the Office de la Naissance et de l’Enfance (ONE) granted in favour of a competitor of our client.

  • Representing a global logistics company in proceedings initiated by an international organisation and the Belgian State following our client’s attachment of assets in a case which raises complex issues under international and procedural law.

Publications and insights

Sign up for updates
    • 12/02/2020
    • Articles

    UK Competition and Markets Authority Consolidates Hydrocortisone Probe On Account of Excessive Pricing and Other Competition Violations

    The UK Competition and Markets Authority announced this morning that it has issued a supplementary statement of objections (“SSO”) in its inquiry into alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct in relation to the supply of hydrocortisone tablets in the UK (see, attachment). The CMA has been conducting three separate investigations in this matter and has issued previous statements of objections on four occasions between December 2016 and February 2019 (see, Van Bael & Bellis Life Sciences Newsflash of 6 March 2017). The new SSO has brought all these cases together and has allowed the CMA to reconsider specific aspects of its provisional findings in the previous statements of objections. The CMA accuses a range of companies, including Auden Mckenzie and its successor Accord-UK (previously: Actavis UK), Waymade and Advanz Pharma (previously: Concordia and AMCo), of having charged excessive and unfair prices for hydrocortisone tablets and having entered into agreements that cemented a prevailing dominant position on the market. The CMA also seeks to attribute liability to other parties which at various points in time had ownership of some of the accused firms. Hydrocortisone tablets are the primary treatment for people suffering from the life-threatening Addison's disease which causes adrenal glands to produce insufficient amounts of natural steroid hormones. According to the CMA, there are limited alternative treatments for hydrocortisone tablets.

    Read more
    • 07/02/2020
    • Articles

    Belgian Council of State Clarifies Role of Concerned Member States in Decentralised Marketing Authorisation Procedure

    On 16 January 2020 the Belgian Council of State reaffirmed the limited discretionary powers of a concerned Member State to call into question the assessments carried out by the Reference Member State in a decentralised procedure. It relied heavily on the case law of the Court of Justice of the European Union in the field. Please find attached a note on the judgment as well as its text.

    Read more
    • 03/02/2020
    • Articles

    Belgium - Medicine Shortages

    The Belgian Official Journal publishes today a Law of 20 December 2019 modifying various laws to tackle medicine shortages (Wet van 20 december 2019 tot wijziging van diverse wetgevingen wat de tekorten aan geneesmiddelen betreft/Loi du 20 décembre 2020 modifiant diverses législations, en ce qui concerne les pénuries de medicaments – the Law). For a summary of the Law’s key features, we refer to the Van Bael & Bellis Life Sciences Newsflash of 20 December 2019. The Royal Decrees that will complement the Law have not yet been published. We understand this still may take some time. The Law will enter into force on 13 February 2020 (i.e., 10 days following its publication in the Belgian Official Journal), with the exception of Articles 2 and 4 that started to apply on 31 January 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *